Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors

NCT00133887 Phase 3 COMPLETED

In a population of kidney transplant recipients having developed a first squamous cell carcinoma, the aim of the study is to assess the incidence of subsequent skin cancers over 2 years in patients who are switched to rapamycin as compared to patients who are maintained under calcineurin inhibitors.

Details

Lead sponsor	Hospices Civils de Lyon
Phase	Phase 3
Status	COMPLETED
Enrolment	77
Start date	2004-04
Completion	2014-05

Conditions

• Skin Cancer
• Kidney Transplantation

Interventions

• rapamycin
• ciclosporine
• tacrolimus

Primary outcomes

• To assess the incidence of new squamous cell carcinoma in kidney transplant recipients — during 5 years

Countries

France